Answers are grounded in this paper and cite their sources.
Breast cancer is the most common cancer among women worldwide.In this study, different derivatives of benzoxazole-coupled azetidinone (DJ1-DJ20) were designed and investigated for antibreast cancer activity targeting a newly recognized receptor, PPARG (PDB:1FM9).These derivatives were designed with varying properties of substituent, such as hydrogen bonding ability, hydrophilicity, hydrophobicity, steric, and electronic effects.Firstly, designed compounds (DJ1-DJ20) were docked with receptor PPARG (PDB:1FM9), and the docking score was in the range of -5.180 to -8.485 kcal/mol.For further analysis, compounds having maximum interaction with receptors were selected based on the docking score greater than 7.5 kcal/mol.The selected compounds MM/GBSA, ADMET properties, pharmacophore modelling, and antibreast cancer properties were evaluated using computational tools, respectively.Among all the compounds, DJ10 showed the best interaction with receptors with the highest dock score of -8.485 kcal/mol and molecular mechanics with a generalized born and surface area solvation (MM/GBSA) score of -72.09 kcal/mol.Apart from these, all-selected compounds' physiochemical and druggable properties were within prescribed limits and adhered to Lipinski's rule of five and rule of three.Pharmacophore modelling showed the presence of steric and electronic features in the ligands to have supramolecular interaction with the PPARG receptor to produce a biological response.Finally, the selected compound's antibreast cancer properties were evaluated using PASS online tool to be antibreast cancer molecules with the highest possibility for compound DJ10 with a pharmacological active value of 0.293.
No takes yet. Share an insight, caveat, or question.
Dheeraj et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: